Hikma launches generic Xeloda in the US

Hikma Pharmaceuticals announced yesterday that its US affiliate West-Ward Pharmaceuticals, has launched a generic version of Genentech’s cancer treatment drug Xeloda (capecitabine) in the US.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Hikma ‘skinny’ label does not infringe Amarin patents

6 January 2022 Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.

Africa

Hikma and Vectura collaborate to develop GSK generics

12 November 2018 Jordan-based Hikma Pharmaceuticals and British pharmaceutical company Vectura Group have united to develop generic versions of GSK’s Ellipta respiratory products.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Hikma launches generic Xeloda in the US

More on this story

Editor's picks

Editor's picks

More features